TAK-137 – (1358749-55-9)

TAK-137 is a novel AMPA receptor potentiator that exhibits a lower agonistic effect compared to other similar compounds, such as LY451646. This unique characteristic is attributed to its structural interference at Ser743 in the AMPA receptor, which reduces the risk of bell-shaped response and seizure.

TAK-137 has demonstrated potent cognitive improvement in both rats and monkeys, with a wider safety margin against seizure compared to LY451646. In rodent studies, TAK-137 induced brain-derived neurotrophic factor (BDNF) production and enhanced neural progenitor proliferation over a broader range of doses. These findings suggest that TAK-137 could be a promising therapeutic option for treating psychiatric and neurological diseases, offering a safer and more effective alternative to existing AMPA receptor potentiators.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://pubchem.ncbi.nlm.nih.gov/compound/56649286
https://www.medkoo.com/products/42777
https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1002/prp2.479
https://www.nature.com/articles/s41386-018-0213-7